Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation. It is to be tested whether the reduction from 4 to 2 cycles of ABVD and/or the reduction of the radiation dose from 30 to 20 Gy is feasible without a loss of efficacy.


Options:
A: Arm Label: Brentuximab Vedotin + Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: brentuximab vedotin, Drug: nivolumab | Intervention Type: DRUG; Name: brentuximab vedotin; Assigned to Arm(s): Brentuximab Vedotin + Nivolumab | Intervention Type: DRUG; Name: nivolumab; Assigned to Arm(s): Brentuximab Vedotin + Nivolumab
B: Arm Label: Nivolumab monotherapy (Dose Escalation); Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Nivolumab + Lirilumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Lirilumab | Arm Label: Nivo + Dara + Pom + Dexa vs. Nivo + Dara; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab, Drug: Pomalidomide, Drug: Dexamethasone | Arm Label: Daratumumab vs. Nivolumab + Daratumumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara, Nivolumab + Ipilimumab, Nivolumab + Lirilumab, Nivolumab monotherapy (Dose Escalation) | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: BIOLOGICAL; Name: Lirilumab; Assigned to Arm(s): Nivolumab + Lirilumab | Intervention Type: BIOLOGICAL; Name: Daratumumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Pomalidomide; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: C